Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fecal microbiota transplant (Jinling Hospital)
- Development stage
- Unknown
- Lead developer
- Jinling Hospital
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Intranasal
01
Overview
Fecal microbiota transplantation (FMT) is an investigational live biotherapeutic therapy involving the transfer of fecal matter from a healthy donor to a recipient to restore a healthy gut microbiome. [2, 14] The specific product developed by Jinling Hospital, China, is being evaluated for the treatment of slow transit constipation (STC). [3, 12] A Phase 2 randomized clinical trial (NCT02526849) investigated the efficacy and safety of FMT administered via a nasointestinal tube in adult patients with STC. [3, 8] The presumed mechanism of action is the restoration of microbial diversity and balance in the recipient's gut, which is often disrupted in patients with constipation. [1] This can lead to the modulation of gut motility, metabolic pathways (such as bile acid metabolism), and intestinal barrier integrity, ultimately improving bowel function and alleviating constipation symptoms. [1, 2, 11]
- Other names
- FMTfecal bacteriotherapystool transplant
Beyond the preview
Go deeper on fecal microbiota transplant (Jinling Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fecal microbiota transplant (Jinling Hospital).